OCT 11, 2018 9:00 AM PDT

Discovering Cellular Mechanisms and Markers in Anti-PD1 Non-Responders Through Ingenuity Pathway Analysis and Oncoland

Sponsored by: QIAGEN
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Senior Field Application Scientist, QIAGEN Advanced Genomics
    Biography
      Devendra (Dev) received his PhD from University of California San Diego(UCSD) Biomedical Sciences graduate program and did postdoctoral studies under both academic and pharmaceutical settings. During his post-doctoral studies, he focused on cellular mechanisms regulating stem cells and cancer stem cells through next-gen sequencing data generation, analysis, interpretation and mining. Dev joined QIAGEN as a field application scientist in 2015. In the past 3 years, he has provided trainings to many pharma, biotech, academic and government investigators for different QIAGEN bioinformatics software. In addition, he has helped many of these users troubleshoot problems with their existing workflows and design new workflows.

    Abstract

    In the last two decades, large amount of next-generation sequencing (NGS) and -omics data has been generated in the field of immuno-oncology. Generating hypotheses by analyzing hundreds if not thousands of differentially expressed genes from expression studies and mining information from large amount of publicly available NGS and -omics data can be a very daunting task. QIAGEN’s Oncoland/Arraystudio (from Omicsoft) and Ingenuity Pathway Analysis (IPA) software provide with a set of tools and functionalities to do analysis and interpretation of NGS data to generate meaningful hypotheses and the ability to mine and compare information across a very large number of datasets curated from publicly available from sources such as GEO, SRA, TCGA, GTEX and others. In this webinar, we use gene expression data from a clinical study (GSE67501) focused on understanding the mechanism underlying anti-PD-1 therapy failure in advanced renal cell carcinoma patients. Using this data and the data curated from TCGA and other sources, it will be demonstrated how Arraystudio and Ingenuity Pathway Analysis can be used to generate hypotheses for mechanism of action and to discover potential targets and biomarkers.

    Learning Objectives: 

    1. Introduction to databases backing Ingenuity Pathway Analysis and Oncoland
    2. Studying potential biomarkers and targets through Oncoland’s data mining and comparison tools
    3. Generation of peer-reviewed literature backed hypotheses through Ingenuity Pathway Analysis


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    Loading Comments...
    Show Resources
    Attendees
    • See more